Tag - BCTX

Developments

BriaCell expands pipeline to ovarian cancer candidate

BriaCell Therapeutics (NASDAQ: BCTX, BCTXL; TSX: BCT) has announced progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer. According to the...

May 15, 2026

Developments

FDA clears BriaCell pivotal study in breast cancer

The FDA approved BriaCell Therapeutics’ (NASDAQ:BCTX; TSX: BCT) pivotal registrational study design for Bria-IMT in combination with a checkpoint inhibitor in advanced metastatic breast cancer, including the study...

June 27, 2023

Tag - BCTX

BriaCell expands pipeline to ovarian cancer candidate

FDA clears BriaCell pivotal study in breast cancer

Subscribe